Calypso Biotech SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Calypso Biotech SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11255
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Calypso Biotech SA (Calypso) is a biopharmaceutical company that develops antibody therapies. The company provides pipeline products such as CALY-0001 and CALY-0002. Its CALY-0001 therapeutic antibody is used in the treatment of Crohn’s disease; and CALY-0002 a humanized monoclonal antibody used in the treatment of refractory celiac disease. Its target therapy areas include gastro-intestinal diseases such as gastric and pancreatic cancer, inflammatory bowel disease. Calypso therapy areas are fibrotic diseases, metastatic cancer, Crohn’s disease and refractory celiac disease. The company develops humanized or fully human monoclonal antibodies. It partners with pharmaceutical companies. Calypso is headquartered in Geneva, Switzerland.

Calypso Biotech SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Calypso Biotech SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Calypso Biotech To Raise US$3.2 Million In Seed Financing 10
Partnerships 11
Fusion Antibodies Enters into Agreement with Calypso Biotech 11
Licensing Agreements 12
EA Pharma Enters into Licensing Agreement with Calypso Biotech 12
Calypso Biotech Enters Into Licensing Agreement With iDD Biotech 13
Calypso Biotech SA – Key Competitors 14
Calypso Biotech SA – Key Employees 15
Calypso Biotech SA – Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Calypso Biotech SA, Pharmaceuticals & Healthcare, Key Facts 2
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Calypso Biotech SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Calypso Biotech SA, Deals By Therapy Area, 2012 to YTD 2018 8
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Calypso Biotech To Raise US$3.2 Million In Seed Financing 10
Fusion Antibodies Enters into Agreement with Calypso Biotech 11
EA Pharma Enters into Licensing Agreement with Calypso Biotech 12
Calypso Biotech Enters Into Licensing Agreement With iDD Biotech 13
Calypso Biotech SA, Key Competitors 14
Calypso Biotech SA, Key Employees 15

List of Figures
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Calypso Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Calypso Biotech SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Simons Group Ltd:企業の戦略・SWOT・財務情報
    Simons Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Simons Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Patterson-UTI Energy Inc (PTEN):石油・ガス:M&Aディール及び事業提携情報
    Summary Patterson-UTI Energy Inc (Patterson) is an oilfield service provider. It offers onshore contract drilling and pressure pumping services to oil and gas exploration and production companies. The company offers pressure pumping services such as well stimulation and cementing for completion of n …
  • Seek Limited
    Seek Limited - Strategy, SWOT and Corporate Finance Report Summary Seek Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Uniper SE (UN01):企業の財務・戦略的SWOT分析
    Uniper SE (UN01) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Alphatec Holdings Inc (ATEC)-医療機器分野:企業M&A・提携分析
    Summary Alphatec Holdings Inc (Alphatec) is a medical technology company that carries out the design, development, manufacturing and marketing of implants for the surgical treatment of spine disorders. Its major products include anterior cervical plate system, posterior cervico/thoracic fixation sys …
  • Senhwa Biosciences Inc (6492)-製薬・医療分野:企業M&A・提携分析
    Summary Senhwa Biosciences Inc (Senhwa) is a drug development company that develops small molecule drugs for the treatment of cancer. The company’s products include CX-5461 and CX-4945. Its CX-5461 is a p53 activating Pol I inhibitor and anticancer compound for treating hematological malignancies. S …
  • Cerenis Therapeutics Holding SA (CEREN):企業の財務・戦略的SWOT分析
    Summary Cerenis Therapeutics Holding SA (Cerenis) is a biopharmaceutical company that discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic …
  • Strides Pharma Science Limited (STAR):医療機器:M&Aディール及び事業提携情報
    Summary Strides Pharma Science Limited (Strides Pharma), formerly Strides Shasun Ltd, is a pharmaceutical company which offers generic products. It focuses on the development and manufacture of intellectual property- led niche pharmaceutical products, over-the-counter drugs and nutraceuticals. The c …
  • Uflex Limited:企業の戦略・SWOT・財務情報
    Uflex Limited - Strategy, SWOT and Corporate Finance Report Summary Uflex Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Credit Du Nord Sa:企業の戦略・SWOT・財務分析
    Credit Du Nord Sa - Strategy, SWOT and Corporate Finance Report Summary Credit Du Nord Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Weifa ASA (WEIFA)-製薬・医療分野:企業M&A・提携分析
    Summary Weifa ASA (Weifa), formerly Aqualis ASA, is a pharmaceutical company that conducts the research and development, manufacture, distribution and sales of pharmaceutical products, lifestyle products and solutions. The company has over the counter (OTC) pharmaceutical market in Norway offering p …
  • Centrexion Therapeutics Corp (CNTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Centrexion Therapeutics Corp (Centrexion Therapeutics), formerly Centrexion Corp is a developer of clinical pipelines of novel and non opioid chronic pain therapy products. The company offers products such as CNTX-4975, CNTX- 0290, CNTX-6970, CNTX-2022, CNTX-6016 and Intrathecalplatform. Its …
  • Titan Pharmaceuticals Inc (TTNP):医療機器:M&Aディール及び事業提携情報
    Summary Titan Pharmaceuticals Inc (Titan) is a pharmaceutical company that develops therapeutics for the treatment of serious medical disorders. The company develops drugs using ProNeura, a proprietary drug delivery platform, for the treatment of chronic diseases. It product portfolio provides probu …
  • Mymetics Corp (MYMX):製薬・医療:M&Aディール及び事業提携情報
    Summary Mymetics Corp (Mymetics) is a biotechnology company that develops next-generation prophylactic vaccines for infectious diseases. The company's product pipeline includes vaccine candidates that target HIV-1/AIDS, chikungunya, intranasal influenza, malaria, herpes simplex virus (HSV) and respi …
  • Exorka GmbH:企業の戦略的SWOT分析
    Exorka GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • BioElectronics Corp (BIEL):企業の財務・戦略的SWOT分析
    BioElectronics Corp (BIEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Bank Pekao SA:戦略・SWOT・企業財務分析
    Bank Pekao SA - Strategy, SWOT and Corporate Finance Report Summary Bank Pekao SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Hovnanian Enterprises Inc:企業の戦略・SWOT・財務分析
    Hovnanian Enterprises Inc - Strategy, SWOT and Corporate Finance Report Summary Hovnanian Enterprises Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Kirby Corporation:戦略・SWOT・企業財務分析
    Kirby Corporation - Strategy, SWOT and Corporate Finance Report Summary Kirby Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Albireo Pharma Inc (ALBO):製薬・医療:M&Aディール及び事業提携情報
    Summary Albireo Pharma Inc (Albireo), formerly Biodel Inc., focuses on the development and commercialization of innovative bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal (GI) disorders and diseases where inappropriate flow of bile causes severe med …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆